secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001437749-25-034446
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q3 net loss $4.4M; cash $21.3M; Niyad study on track for H1 2026
-------------------------------------------------------------------------

- Net loss $4.4M ($0.11/sh) vs $3.4M ($0.13/sh) in Q3 2024.
- Cash and investments $21.3M at Sept 30; sufficient through potential Niyad PMA approval late 2026.
- Closed $17M first tranche financing led by CorMedix (CRMD); second tranche up to $29M conditional.
- Five of nine NEPHRO trial sites activated; enrollment completion expected H1 2026.
- Reduced 2025 cash operating expense guidance to $14-15M from $16-17M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/0001437749-25-034446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925034446/acrx20251108_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer